{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00","value":"1.14"},{"groupId":"OG001","spread":"9.49","value":"1.07"}]}],"title":"Bendamustine; n=5, 37"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00","value":"1.14"},{"groupId":"OG001","spread":"9.53","value":"1.07"}]}],"title":"Metabolite M3; n=5, 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00","value":"1.14"},{"groupId":"OG001","spread":"9.49","value":"1.07"}]}],"title":"Metabolite M4; n=5, 37"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Bendamustine 90 mg/m\\^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of a 21-day Induction cycle, with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"OG000","title":"Bendamustine 90 mg/m^2"},{"description":"Bendamustine 120 mg/m\\^2 administered as an IV infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"OG001","title":"Bendamustine 120 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic analysis set included all participants who were in the safety analysis set (ie, those treated at any dose of bendamustine) who had valid pharmacokinetic data; n=number of participants with valid data for this assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.","title":"Time to Maximum Plasma Drug Concentration (Tmax) for Bendamustine and Its Metabolites (M3 and M4)","type":"SECONDARY","unitOfMeasure":"hours"}